Literature DB >> 29094432

Mu opioid receptors in GABAergic neurons of the forebrain promote alcohol reward and drinking.

Sami Ben Hamida1,2, Laura-Joy Boulos1,2, Michael McNicholas2, Pauline Charbogne2,3, Brigitte Lina Kieffer1,2.   

Abstract

Mu opioid receptors (MORs) are widely distributed throughout brain reward circuits and their role in drug and social reward is well established. Substantial evidence has implicated MOR and the endogenous opioid system in alcohol reward, but circuit mechanisms of MOR-mediated alcohol reward and intake behavior remain elusive, and have not been investigated by genetic approaches. We recently created conditional knockout (KO) mice targeting the Oprm1 gene in GABAergic forebrain neurons. These mice (Dlx-MOR KO) show a major MOR deletion in the striatum, whereas receptors in midbrain (including the Ventral Tegmental Area or VTA) and hindbrain are intact. Here, we compared alcohol-drinking behavior and rewarding effects in total (MOR KO) and conditional KO mice. Concordant with our previous work, MOR KO mice drank less alcohol in continuous and intermittent two-bottle choice protocols. Remarkably, Dlx-MOR KO mice showed reduced drinking similar to MOR KO mice, demonstrating that MOR in the forebrain is responsible for the observed phenotype. Further, alcohol-induced conditioned place preference was detected in control but not MOR KO mice, indicating that MOR is essential for alcohol reward and again, Dlx-MOR KO recapitulated the MOR KO phenotype. Taste preference and blood alcohol levels were otherwise unchanged in mutant lines. Together, our data demonstrate that MOR expressed in forebrain GABAergic neurons is essential for alcohol reward-driven behaviors, including drinking and place conditioning. Challenging the prevailing VTA-centric hypothesis, this study reveals another mechanism of MOR-mediated alcohol reward and consumption, which does not necessarily require local VTA MORs but rather engages striatal MOR-dependent mechanisms.
© 2017 Society for the Study of Addiction.

Entities:  

Keywords:  alcohol intake; forebrain GABAergic neurons; mu opioid receptor

Year:  2017        PMID: 29094432      PMCID: PMC5932272          DOI: 10.1111/adb.12576

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  49 in total

1.  mu-Opioid receptor knockout mice do not self-administer alcohol.

Authors:  A J Roberts; J S McDonald; C J Heyser; B L Kieffer; H W Matthes; G F Koob; L H Gold
Journal:  J Pharmacol Exp Ther       Date:  2000-06       Impact factor: 4.030

2.  Increased mesolimbic cue-reactivity in carriers of the mu-opioid-receptor gene OPRM1 A118G polymorphism predicts drinking outcome: a functional imaging study in alcohol dependent subjects.

Authors:  Patrick Bach; Sabine Vollsta Dt-Klein; Martina Kirsch; Sabine Hoffmann; Anne Jorde; Josef Frank; Katrin Charlet; Anne Beck; Andreas Heinz; Henrik Walter; Wolfgang H Sommer; Rainer Spanagel; Marcella Rietschel; Falk Kiefer
Journal:  Eur Neuropsychopharmacol       Date:  2015-04-18       Impact factor: 4.600

Review 3.  Understanding opioid reward.

Authors:  Howard L Fields; Elyssa B Margolis
Journal:  Trends Neurosci       Date:  2015-01-29       Impact factor: 13.837

4.  Chemosensory factors influencing alcohol perception, preferences, and consumption.

Authors:  Alexander A Bachmanov; Stephen W Kiefer; Juan Carlos Molina; Michael G Tordoff; Valerie B Duffy; Linda M Bartoshuk; Julie A Mennella
Journal:  Alcohol Clin Exp Res       Date:  2003-02       Impact factor: 3.455

5.  Interactive effects of OPRM1 and DAT1 genetic variation on subjective responses to alcohol.

Authors:  Lara A Ray; Spencer Bujarski; Lindsay M Squeglia; James R Ashenhurst; Raymond F Anton
Journal:  Alcohol Alcohol       Date:  2014-01-13       Impact factor: 2.826

6.  A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence.

Authors:  J Balldin; M Berglund; S Borg; Marianne Månsson; P Bendtsen; J Franck; L Gustafsson; J Halldin; L H Nilsson; G Stolt; A Willander
Journal:  Alcohol Clin Exp Res       Date:  2003-07       Impact factor: 3.455

7.  A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial.

Authors:  José Guardia; Carlos Caso; Francisco Arias; Antoni Gual; Jordi Sanahuja; Marisa Ramírez; Ildefonso Mengual; Begoña Gonzalvo; Lidia Segura; Joan Trujols; Miguel Casas
Journal:  Alcohol Clin Exp Res       Date:  2002-09       Impact factor: 3.455

Review 8.  Intermittent ethanol access schedule in rats as a preclinical model of alcohol abuse.

Authors:  Sebastien Carnicella; Dorit Ron; Segev Barak
Journal:  Alcohol       Date:  2014-03-15       Impact factor: 2.405

Review 9.  Cortico-Basal Ganglia reward network: microcircuitry.

Authors:  Susan R Sesack; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

10.  Comparing Nalmefene and Naltrexone in Alcohol Dependence: Are there any Differences? Results from an Indirect Meta-Analysis.

Authors:  M Soyka; M Friede; J Schnitker
Journal:  Pharmacopsychiatry       Date:  2016-02-04       Impact factor: 5.788

View more
  10 in total

1.  Mu-Opioid Receptors Expressed in Glutamatergic Neurons are Essential for Morphine Withdrawal.

Authors:  Xin-Yan Zhang; Qing Li; Ye Dong; Wei Yan; Kun Song; Yong-Qin Lin; Yan-Gang Sun
Journal:  Neurosci Bull       Date:  2020-05-25       Impact factor: 5.203

Review 2.  Involvement of Activated Brain Stress Responsive Systems in Excessive and "Relapse" Alcohol Drinking in Rodent Models: Implications for Therapeutics.

Authors:  Yan Zhou; Mary Jeanne Kreek
Journal:  J Pharmacol Exp Ther       Date:  2018-04-18       Impact factor: 4.030

Review 3.  Behavioral, neurobiological, and neurochemical mechanisms of ethanol self-administration: A translational review.

Authors:  Ashley A Vena; Shannon L Zandy; Roberto U Cofresí; Rueben A Gonzales
Journal:  Pharmacol Ther       Date:  2020-05-11       Impact factor: 12.310

4.  Nuclear transcriptional changes in hypothalamus of Pomc enhancer knockout mice after excessive alcohol drinking.

Authors:  Yan Zhou; Yupu Liang; Malcolm J Low; Mary J Kreek
Journal:  Genes Brain Behav       Date:  2019-08-08       Impact factor: 3.449

5.  Mu opioid receptors in the medial habenula contribute to naloxone aversion.

Authors:  L J Boulos; S Ben Hamida; J Bailly; M Maitra; A T Ehrlich; C Gavériaux-Ruff; E Darcq; B L Kieffer
Journal:  Neuropsychopharmacology       Date:  2019-04-20       Impact factor: 7.853

6.  Mechanisms Underlying Mu Opioid Receptor Effects on Parallel Fiber-Purkinje Cell Synaptic Transmission in Mouse Cerebellar Cortex.

Authors:  Yi Yang; Jin Bai; Jia-Yue Sun; Ting Ye; Lu Zhang; Feng-Ying Wu; Jun Nan; Yan Lan
Journal:  Front Synaptic Neurosci       Date:  2022-04-25

7.  An analysis of the effect of mu-opioid receptor gene (OPRM1) promoter region DNA methylation on the response of naltrexone treatment of alcohol dependence.

Authors:  Yufei Lin; Henry R Kranzler; Lindsay A Farrer; Hongqin Xu; David C Henderson; Huiping Zhang
Journal:  Pharmacogenomics J       Date:  2020-02-07       Impact factor: 3.550

8.  Mu opioid receptors on vGluT2-expressing glutamatergic neurons modulate opioid reward.

Authors:  Kaitlin C Reeves; Megan J Kube; Gregory G Grecco; Brandon M Fritz; Braulio Muñoz; Fuqin Yin; Yong Gao; David L Haggerty; Hunter J Hoffman; Brady K Atwood
Journal:  Addict Biol       Date:  2020-07-20       Impact factor: 4.280

9.  Mapping of Morphine-Induced OPRM1 Gene Expression Pattern in the Adult Zebrafish Brain.

Authors:  Mageswary Sivalingam; Satoshi Ogawa; Ishwar S Parhar
Journal:  Front Neuroanat       Date:  2020-02-20       Impact factor: 3.856

10.  μ-Opioid Receptors on Distinct Neuronal Populations Mediate Different Aspects of Opioid Reward-Related Behaviors.

Authors:  Amie L Severino; Nitish Mittal; Joshua K Hakimian; Nathanial Velarde; Ani Minasyan; Ralph Albert; Carlos Torres; Nicole Romaneschi; Camille Johnston; Suchi Tiwari; Alex S Lee; Anna M Taylor; Claire Gavériaux-Ruff; Brigitte L Kieffer; Christopher J Evans; Catherine M Cahill; Wendy M Walwyn
Journal:  eNeuro       Date:  2020-09-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.